Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Byrd

Showing results (171-180 of 188) with videos related to

Pageof 19
Sort By:
Annals of Hematology|May 6, 2004
G3139, a BCL-2 antisense oligo-nucleotide, in AMLG Marcucci, W Stock, G Dai, et al.
Leukemia|January 22, 2014
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia modelK A Beckwith, F W Frissora, M R Stefanovski, et al.
Leukemia|February 20, 2003
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cellsM I Klisovic, E A Maghraby, M R Parthun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461J C Byrd, R B Weiss, D C Arthur, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 8, 2001
CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemiaS P Treon, T B Agus, B Link, et al.
Annals of Hematology|May 6, 2004
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461C D Bloomfield, A S Ruppert, K Mrózek, et al.
Leukemia|March 22, 2017
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemiaA-K Eisfeld, K Mrózek, J Kohlschmidt, et al.
Leukemia|January 14, 2014
Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cellsY Zhong, D El-Gamal, J A Dubovsky, et al.
The Journal of Experimental Medicine|December 26, 2001
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemiaA Rosenwald, A A Alizadeh, G Widhopf, et al.
Leukemia|November 16, 2016
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemiaA-K Eisfeld, J Kohlschmidt, S Schwind, et al.
Pageof 19

Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
Annals of Hematology|May 6, 2004
G3139, a BCL-2 antisense oligo-nucleotide, in AMLG Marcucci, W Stock, G Dai, et al.
Leukemia|January 22, 2014
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia modelK A Beckwith, F W Frissora, M R Stefanovski, et al.
Leukemia|February 20, 2003
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cellsM I Klisovic, E A Maghraby, M R Parthun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461J C Byrd, R B Weiss, D C Arthur, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 8, 2001
CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemiaS P Treon, T B Agus, B Link, et al.
Annals of Hematology|May 6, 2004
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461C D Bloomfield, A S Ruppert, K Mrózek, et al.
Leukemia|March 22, 2017
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemiaA-K Eisfeld, K Mrózek, J Kohlschmidt, et al.
Leukemia|January 14, 2014
Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cellsY Zhong, D El-Gamal, J A Dubovsky, et al.
The Journal of Experimental Medicine|December 26, 2001
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemiaA Rosenwald, A A Alizadeh, G Widhopf, et al.
Leukemia|November 16, 2016
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemiaA-K Eisfeld, J Kohlschmidt, S Schwind, et al.
Pageof 19